Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Epidemiologic and genomewide association studies have linked loss-of-function variants in ANGPTL3, encoding angiopoietin-like 3, with low levels of plasma lipoproteins. METHODS: We evaluated antisense oligonucleotides (ASOs) targeting Angptl3 messenger RNA (mRNA) for effects on plasma lipid levels, triglyceride clearance, liver triglyceride content, insulin sensitivity, and atherosclerosis in mice. Subsequently, 44 human participants (with triglyceride levels of either 90 to 150 mg per deciliter [1.0 to 1.7 mmol per liter] or >150 mg per deciliter, depending on the dose group) were randomly assigned to receive subcutaneous injections of placebo or an antisense oligonucleotide targeting ANGPTL3 mRNA in a single dose (20, 40, or 80 mg) or multiple doses (10, 20, 40, or 60 mg per week for 6 weeks). The main end points were safety, side-effect profile, pharmacokinetic and pharmacodynamic measures, and changes in levels of lipids and lipoproteins. RESULTS: The treated mice had dose-dependent reductions in levels of hepatic Angptl3 mRNA, Angptl3 protein, triglycerides, and low-density lipoprotein (LDL) cholesterol, as well as reductions in liver triglyceride content and atherosclerosis progression and increases in insulin sensitivity. After 6 weeks of treatment, persons in the multiple-dose groups had reductions in levels of ANGPTL3 protein (reductions of 46.6 to 84.5% from baseline, P<0.01 for all doses vs. placebo) and in levels of triglycerides (reductions of 33.2 to 63.1%), LDL cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein B (3.4 to 25.7%), and apolipoprotein C-III (18.9 to 58.8%). Three participants who received the antisense oligonucleotide and three who received placebo reported dizziness or headache. There were no serious adverse events. CONCLUSIONS: Oligonucleotides targeting mouse Angptl3 retarded the progression of atherosclerosis and reduced levels of atherogenic lipoproteins in mice. Use of the same strategy to target human ANGPTL3 reduced levels of atherogenic lipoproteins in humans. (Funded by Ionis Pharmaceuticals; ClinicalTrials.gov number, NCT02709850 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“Interestingly, the LDL-C lowering effects of ANGPTL3 inhibition with either monoclonal antibodies or antisense oligonucleotides seems to be LDL receptor (LDLR) independent since marked LDL-C lowering is observed in both Ldlr knock-out (KO) mice6,8 and patients with homozygous familial hypercholesterolemia (hoFH).9”
In the citing paper
“A decrease in VLDL-TG secretion, but not in VLDL apoB secretion or VLDL clearance, was observed in mouse models treated with a monoclonal antibody6 or antisense oligonucleotides8 against ANGPTL3.”
In the citing paper
“In initial studies, treatment with Vupanorsen was associated with a 33%–63% decrease in triglycerides as well as reductions in Apo-C III, remnant and total cholesterol, HDL-C, and LDL-C (169).”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [169]
In the citing paper
“In a dose-finding study in HTG patients, IONIS-ANGPTL3-LRx reduced TG and LDL-C by up to 63.1% and 32.9%, respectively.82”
From Clinical review on triglycerides (2020) · cites this paper as [82]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754
Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754
Self-citationAntisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528
Self-citationInactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
Self-citationWallace, C., Newhouse, S. J., Braund, P., Zhang, F., Tobin, M., Falchi, M., Ahmadi, K., Dobson, R. J., Marçano, A. C. B., Hajat, C., et al. (2008) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2007.11.001 · Cited by 439
Research works printed but not linked: 1
- Romeo S, 2009, J Clin Invest, 119, 70
Cited by
Items 401–500 of 575
RNA Therapies in Cardio-Kidney-Metabolic Syndrome: Advancing Disease Management
Mohammadi, A., Karimian, A., Shokri, K., Mohammadi, A., Karzar, N. H., Bahar, R., Radfar, A., Pakyari, M., & Tehrani, B. N. (2025) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-025-10603-4 · Cited by 8
Genetic Assessment and Clinical Correlates in Severe Hypertriglyceridemia: A Systematic Review
Luca, C. D., Ciciola, P., D’Errico, G., Taranto, M. D. D., Fortunato, G., Gross, C., Garn, J., Iannuzzo, G., Minno, M. N. D. D., & Calcaterra, I. L. (2025) · Genes · doi:10.3390/genes16111377 · Cited by 9
Bazarbashi, N., & Miller, M. J. (2022) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.11.006 · Cited by 10
Treating Cardiovascular Disease with Liver Genome Engineering
Hurley, A. E., & Lagor, W. R. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00986-z · Cited by 7
RNA in cardiovascular disease: A new frontier of personalized medicine
Abdul-Rahman, T., Lizano-Jubert, I., Bliss, Z. S. B., Garg, N. K., Meale, E., Roy, P., Crino, S. A., Bethineedi, L. D., Miteu, G. D., Awuah, W. A., et al. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.016 · Cited by 7
Young, E. P., & Stitziel, N. O. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-041717-085853 · Cited by 7
Coronary artery disease: differential expression of ceRNAs and interaction analyses
Kang, S., Ye, Y., Xia, G., & Liu, H. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-3487 · Cited by 7
Managing of dyslipidaemia characterized by accumulation of triglyceride-rich lipoproteins
Visser, J., van Zwol, W., & Kuivenhoven, J. A. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00979-y · Cited by 7
Khoury, É., Croteau, L., Lauzière, A., & Gaudet, D. (2022) · Future Cardiology · doi:10.2217/fca-2021-0149 · Cited by 8
Innate Immunity in Cardiovascular Diseases—Identification of Novel Molecular Players and Targets
Poller, W. C., Heidecker, B., Ammirati, E., Kuss, A. W., Tzvetkova, A., Poller, W. C., Skurk, C., & Haghikia, A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12010335 · Cited by 8
Gene Delivery in Lipid Research and Therapies
Giorgi, M. D., & Lagor, W. R. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-1-62 · Cited by 7
Recent insights into low-density lipoprotein metabolism and therapy
Pirillo, A., Catapano, A. L., & Norata, G. D. (2020) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000727 · Cited by 7
Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects
Filippatos, T. D., Liontos, A., Christopoulou, E. C., & Elisaf, M. (2018) · Current Vascular Pharmacology · doi:10.2174/1570161116666180209112351 · Cited by 8
Emerging Strategies for the Management of Atherogenic Dyslipidaemia
Agarwala, A., & Shapiro, M. D. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.16 · Cited by 7
Focus on the Lymphatic Route to Optimize Drug Delivery in Cardiovascular Medicine
Tessier, N., Moawad, F., Amri, N., Brambilla, D., & Martel, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081200 · Cited by 9
In Search of Patients With Elevated Lp(a)
Tsimikas, S. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.12.036 · Cited by 7
Self-citationAdvancements in Nonviral Gene Editing Strategies for Rare Diseases
Pérez-Maroto, J., Sepp‐Lorenzino, L., Castaño-Esteban, D., Palacios, D., & Sot, B. (2025) · Human Gene Therapy · doi:10.1177/10430342251372056 · Cited by 6
The role of elevated lipoprotein(a) in aortic valve disease: a systematic review
Wambua, P., Wahinya, M., & Khan, Z. U. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1610395 · Cited by 6
Angiopoietin-like protein 3: a novel potential biomarker for nephrotic syndrome in children
Wen, F., Liu, J., Dai, R., Hong, S., Ji, B., Liu, J., Zhang, J., Han, X., Lv, Q., Liu, J., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1113484 · Cited by 6
Ермоленко, В. М. (2024) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2024-28-1-13-29 · Cited by 6
An up-to-date review of emerging biologic therapies for hypercholesterolemia
Tomlinson, B. (2024) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2024.2442455 · Cited by 6
Epigenetic regulation in coronary artery disease: from mechanisms to emerging therapies
Gao, R., Liu, M., Yang, H., Shen, Y., & Xia, N. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1548355 · Cited by 7
New therapeutic approaches for the treatment of hypertriglyceridemia
Gouni‐Berthold, I., & Schwarz, J. (2022) · Herz · doi:10.1007/s00059-022-05113-x · Cited by 6
Peng, Y., Hu, D., Luo, Q., & Peng, D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.863687 · Cited by 6
Khalifeh, M., Santos, R. D., Oskuee, R. K., Badiee, A., Aghaee‐Bakhtiari, S. H., & Sahebkar, A. (2022) · Progress in Lipid Research · doi:10.1016/j.plipres.2022.101197 · Cited by 7
Page, M. M., Bell, D. A., & Watts, G. F. (2019) · Clinical Genetics · doi:10.1111/cge.13685 · Cited by 6
Adrenoceptor‐related decrease in serum triglycerides is independent of PPAR α activation
Konstandi, M., Kypreos, K. E., Matsubara, T., Xepapadaki, E., Shah, Y. M., Krausz, K. W., Andriopoulou, C. E., Kofinas, A., & Gonzalez, F. J. (2019) · FEBS Journal · doi:10.1111/febs.14966 · Cited by 7
Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias?
Lechner, K., Kessler, T., & Schunkert, H. (2020) · Current Cardiology Reports · doi:10.1007/s11886-020-01408-9 · Cited by 6
Surma, S., Romańczyk, M., & Filipiak, K. J. (2021) · Folia Cardiologica · doi:10.5603/fc.2021.0005 · Cited by 6
Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3
Blackburn, N. B., Meikle, P. J., Peralta, J. M., Kumar, S., Leandro, A. C., Bellinger, M. A., Giles, C., Huynh, K., Mahaney, M. C., Göring, H. H. H., et al. (2021) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.120.003232 · Cited by 6
ANGPTL3 and residual atherosclerotic risk: from lipid metabolism to therapeutic targeting
Weng, S., Ding, C., Lin, J., & Chai, D. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1706091 · Cited by 6
Wadström, B. N., Pedersen, K. M., Wulff, A. B., & Nordestgaard, B. G. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.70005 · Cited by 6
A Review of Low-Density Lipoprotein-Lowering Diets in the Age of Anti-Sense Technology
Nestel, P. J., & Mori, T. A. (2023) · Nutrients · doi:10.3390/nu15051249 · Cited by 6
Novel Insights of ANGPTL-3 on Modulating Cholesterol Efflux Capacity Induced by HDL Particle
Lai, M., Jiang, X., Wang, B., Cheng, Y., & Su, X. (2023) · Current Molecular Medicine · doi:10.2174/1566524023666230418104400 · Cited by 6
Recent Updates on Epigenetic-Based Pharmacotherapy for Atherosclerosis
Ariyanto, E. F., Wijaya, I., Pradian, Z. A., Bhaskara, A. P. M., Rahman, P. H. A., & Oktavia, N. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s463221 · Cited by 6
Volta, A., Hovingh, G. K., & Grefhorst, A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000489 · Cited by 5
Regulatory Non-Coding RNAs in Familial Hypercholesterolemia, Theranostic Applications
Alikhani, H. K., Pourhamzeh, M., Seydi, H., Shokoohian, B., Hossein‐Khannazer, N., Jamshidi‐Adegani, F., Al‐Hashmi, S., Hassan, M., & Vosough, M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.894800 · Cited by 6
Ahn, J. E., Terra, S. G., & Liu, J. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12969 · Cited by 5
Recent updates in dyslipidemia management: perspectives in stroke-specific situation
Seo, W., Hosseini, M. B., Bang, O. Y., & Liebeskind, D. S. (2020) · Precision and Future Medicine · doi:10.23838/pfm.2020.00009 · Cited by 5
Hypertriglyceridemia as a multidisciplinary problem of modern medicine
Васильевна, Ц. О., Ozhiganova, N. V., Kastalap, V. V., Саяровна, Б. С., & Latyntseva, L. D. (2020) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2020-9-4-114-123 · Cited by 6
Palmisano, B. T., Zhu, L., Litts, B., Burman, A., Yu, S., Neuman, J. C., Anozie, U., Luu, T. N., Edington, E. M., & Stafford, J. M. (2021) · Metabolites · doi:10.3390/metabo11050330 · Cited by 7
Xu, F., Shen, L., Yang, Y., Kong, L., Zu, W., Tian, D., Xuanchao, C., & Huang, G. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s411483 · Cited by 5
Santos, R. D. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000460 · Cited by 5
Lipoprotein Metabolism and Cholesterol Balance
Acuña, M., & Cohen, D. E. (2020) · Wiley eBooks · doi:10.1002/9781119436812.ch22 · Cited by 6
Advancing RNA-targeted therapy for personalised prevention of coronary disease: focus on ANGPLT3
Landmesser, U., & Lüscher, T. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa790 · Cited by 6
Long-lost friend is back in the game
Kersten, S. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100072 · Cited by 5
Zhang, H., Zhou, Z., Gu, J., Lin, Y., Yan, Y., Chen, X., Fan, M., & Huang, Y. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111282 · Cited by 4
Walker, S. G., Chen, Y., Sylvers-Davie, K. L., Dou, A., Zhen, Y., Qian, Y., Wen, Y., Ehsani, M. E., Smith, S. A., Thapa, R., et al. (2025) · JCI Insight · doi:10.1172/jci.insight.197827 · Cited by 4
Genetic factors contributing to atherosclerosis
Raddatz, M. A., Allayee, H., & Lusis, A. J. (2026) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001286 · Cited by 4
Ossoli, A., Minicocci, I., Turri, M., Costanzo, A. D., D’Erasmo, L., Bini, S., Montavoci, L., Veglia, F., Calabresi, L., & Arca, M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2022.159263 · Cited by 4
Putative medicines that mimic mutations
Kathiresan, S. (2017) · Nature · doi:10.1038/nature23544 · Cited by 4
RNA in the spotlight: the dawn of RNA therapeutics in the treatment of human disease
Stellos, K. (2017) · Cardiovascular Research · doi:10.1093/cvr/cvx170 · Cited by 4
The year in cardiology 2017: prevention
Nordestgaard, B. G., Cosentino, F., Landmesser, U., & Laufs, U. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx766 · Cited by 4
Treatment of Hypertriglyceridemia: A Review of Therapies in the Pipeline
Xu, J., & Ashjian, E. J. (2021) · Journal of Pharmacy Practice · doi:10.1177/08971900211053489 · Cited by 4
Update on management of paediatric dyslipidaemia
Bansal, N., Kumar, S., & Brar, P. C. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000794 · Cited by 4
Association between remnant cholesterol and progression of bioprosthetic valve degeneration
Li, Z., Zhang, B., Salaün, E., Côté, N., Mahjoub, H., Mathieu, P., Dahou, A., Zenses, A., Xu, Y., Pîbarot, P., et al. (2023) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jead159 · Cited by 4
Tackling Residual Atherosclerotic Risk in Statin-Treated Adults: Focus on Emerging Drugs
Takata, K., & Nicholls, S. J. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0312-1 · Cited by 4
Investigational drugs in development for hypertriglyceridemia: a coming-of-age story
Rhainds, D., Brodeur, M. R., & Tardif, J. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1696772 · Cited by 4
Qin, L., Rehemuding, R., Ainiwaer, A., & Ma, X. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i7.2095 · Cited by 4
ANGPTL3 targeting: The power of versatile lipid-lowering
Pessentheiner, A. R., Ramms, B., & Gordts, P. L. S. M. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.002 · Cited by 5
Watts, G. F., Scott, R., Sullivan, D., BAKER, J., Clifton, P. M., Hamilton, J., Given, B. D., Melquist, S., Zhou, R., Gaudet, D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04307-8 · Cited by 3
Wu, X., Yu, J., Ge, B., Wang, J. Y., Han, X., Zhang, C., Mao, X., Kalluru, H., Bramson, C., Terra, S. G., et al. (2024) · Drugs in R&D · doi:10.1007/s40268-024-00467-5 · Cited by 3
Kršek, A., Batičić, L., & Tokmadžić, V. S. (2024) · Cardiogenetics · doi:10.3390/cardiogenetics14030012 · Cited by 5
Inhibition of ANGPTL3 as a Target for Treating Dyslipidemias
Watts, G. F., Chan, D. C., & Raal, F. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00027-3 · Cited by 3
Gerontas, A. K., Avgerinos, D. V., Charitakis, K., Maragou, H., & Drosatos, K. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1231762 · Cited by 3
Wu, T.-C., Hsu, B., Kuo, C., Wang, C., & Tsai, J. (2023) · Life · doi:10.3390/life14010018 · Cited by 6
How to handle hypertriglyceridaemia in acute pancreatitis – Still a vote for conservatives?
Eriksson, M., & Angelin, B. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12971 · Cited by 3
Nuevos tratamientos en la hipertrigliceridemia y en la hiperquilomicronemia
García-Díaz, J. D. D. (2020) · Medicina Clínica · doi:10.1016/j.medcli.2019.11.003 · Cited by 3
A Lipid lover’s Guide to Novel Therapeutics for Lipid and Cardiovascular Risk Reduction
Hritani, R., Hussain, A., Saeed, A., & Agarwala, A. (2021) · Future Cardiology · doi:10.2217/fca-2020-0216 · Cited by 4
Evinacumab bei Patienten mit therapierefraktärer Hypercholesterinämie
Windler, E. E. T., & Nitschmann, S. (2021) · Der Internist · doi:10.1007/s00108-021-01044-7 · Cited by 3
The Role of Extracellular Non-coding RNAs in Atherosclerosis
Cui, Y., Zhou, Y., Gan, N., Xiang, Q., Xia, M., Liao, W., Zheng, X., Peng, J., & Tang, Z. (2022) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-022-10218-z · Cited by 3
Physiological Level of LDL Cholesterol: The Master Key A Nobel Dream Comes True
Morales-Villegas, E., & Ray, K. K. (2017) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000223 · Cited by 3
ANGPTL3 Variants Associate with Lower Levels of Irisin and C-Peptide in a Cohort of Arab Individuals
Alanbaei, M., Abu‐Farha, M., Hebbar, P., Melhem, M., Chandy, B., Anoop, E., Cherian, P., Al‐Khairi, I., Alkayal, F., Al‐Mulla, F., et al. (2021) · Genes · doi:10.3390/genes12050755 · Cited by 4
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Clinical Approach to Assessment and Amelioration of Atherosclerotic Vascular Disease in Diabetes
Goldberg, R. B. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.582826 · Cited by 3
Rader, D. J., & Kathiresan, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00001-9 · Cited by 5
From Bench to Bedside: Current Developments in RNA-Based Therapies for Treatment of Hyperlipidemia
Zhou, Y., & Chen, C. (2022) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.v1i1.141 · Cited by 3
Klose, G., Gouni‐Berthold, I., & März, W. (2023) · Die Innere Medizin · doi:10.1007/s00108-023-01524-y · Cited by 2
RNA inosine sensor-guided TadA mutational scanning for toxicity minimization of adenine base editors
Zhang, C., Chen, Z., Cao, J., Zhang, Z., Li, W.-K., Zhang, X., Chen, J., Liu, J., Yuan, Z., Gao, F., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.10.011 · Cited by 3
Leiviskä, J., Sundvall, J., Jauhiainen, M., Kotseva, K., Tuomilehto, J., Backer, G. D., Tokgözoğlu, L. S., Reiner, Ž., & Bacquer, D. D. (2025) · Clinica Chimica Acta · doi:10.1016/j.cca.2025.120653 · Cited by 2
Zadeh, S. S. T., Toth, P. P., & Banach, M. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1789019 · Cited by 2
Lipid dysregulation in chronic diseases: systems biology and omics perspectives
Majumder, D., Bhattacharya, D., Gill, H. S., Rajeev, M., Sharma, S., Dwivedi, S. P., Nag, M., & Lahiri, D. (2026) · Xenobiotica · doi:10.1080/00498254.2026.2680076 · Cited by 2
Michel, S., Klar, R., & Jaschinski, F. (2021) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0932 · Cited by 2
Муратович, Н. А., & Витальевна, К. К. (2024) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/011871529x305291240715112812 · Cited by 2
ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states
Nagai, T. H., Mizoguchi, T., Wang, Y., Deik, A., Bullock, K. H., Clish, C. B., & Xu, Y. (2025) · Scientific Reports · doi:10.1038/s41598-025-89552-6 · Cited by 2
Tran, H. H.-V., Thu, A., Twayana, A. R., Fuertes, A., Gonzalez, M., Basta, M., James, M., Mahadevaiah, A., Mehta, K. A., Islek, D., et al. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000000976 · Cited by 3
Effects of evolving lipid-lowering drugs on carbohydrate metabolism
Tsimihodimos, V., & Elisaf, M. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.12.012 · Cited by 2
RNA therapies for cardiovascular disease
Laina, A., Vlachogiannis, N. I., Stamatelopoulos, K. S., & Stellos, K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00003-4 · Cited by 2
What is really new in triglyceride guidelines?
Hussain, A., Rifai, M. A., Hermel, M., Slipczuk, L. N., & Virani, S. S. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000802 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Working towards full eradication of lipid-driven cardiovascular risk?
Nurmohamed, N. S., & Stroes, E. S. G. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01600-8 · Cited by 2
Hypertriglyceridaemia: Contemporary management of a neglected cardiovascular risk factor
Khan, T. Z., Schatz, U., Bornstein, S. R., & Barbir, M. (2021) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2021.19 · Cited by 3
Oligonucleotides targeting ANGPTL3
Luo, F., Guo, Y., Li, X., Hu, X., & Fang, Z. (2018) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.10.003 · Cited by 2
Lipid metabolism: spotlight on modulators of lipoprotein lipase activity
Arndt, L., & Burkhardt, R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000501 · Cited by 2
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819460-7.00125-0 · Cited by 2
Zhang, P., Wang, K., Hu, T., Xu, M., You, X., Chen, M., Tang, X. L., Hu, H., Jiang, Y., Zhao, W., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202301564rr · Cited by 1
Lipids, Lipoproteins, and Cardiovascular Outcomes
Sakers, A. P., Mszar, R., & Soffer, D. E. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_9 · Cited by 1
Atherosclerosis and inflammation: therapeutic targets and ways of correction
Клименко, А. А., Andriyashkina, D. Y., & Ogarkova, K. I. (2024) · The Clinician · doi:10.17650/1818-8338-2024-18-1-k696 · Cited by 2
Wang, W., Tang, B., Yuan, S., Luan, H., Qi, T., & Chen, J. R. (2025) · Sexual Medicine · doi:10.1093/sexmed/qfaf076 · Cited by 1
Hou, Y., Zhang, X., Sun, X., Qin, Q., Jia, M., Su, X., & Chen, Y. (2026) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.125.324122 · Cited by 1
Metadata
- Authors
- Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., Baker, B. F., Pham, N. C., Digenio, A., Hughes, S. G., Geary, R. S., Witztum, J. L., Crooke, R. M., & Tsimikas, S.
- Affiliations
- Ionis Pharmaceuticals (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-07-20
- Volume
- 377
- Issue
- 3
- Pages
- 222-232
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2618984243
- Cited by
- 573
- References
- 23
- Citations by year
- 2026: 20 · 2025: 36 · 2024: 48 · 2023: 51 · 2022: 85 · 2021: 86 · 2020: 90 · 2019: 59 · 2018: 72 · 2017: 26
- FWCI
- 52.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- ANGPTL3, antisense oligonucleotides, triglyceride lowering, hypertriglyceridemia, LDL cholesterol, hepatic triglyceride content, atherosclerosis, insulin sensitivity, lipoproteins, apolipoprotein B, apolipoprotein C-III, loss-of-function mutations, pharmacokinetics
- MeSH terms
- Angiopoietin-like Proteins, Angiopoietin-Like Protein 3, Adult, Aged, Animals, Coronary Artery Disease, Disease Models, Animal, Double-Blind Method, Female, Humans, Lipids, Male, Mice, Inbred Strains, Middle Aged, Oligonucleotides, RNA, Messenger, Oligonucleotides, Antisense, Angiopoietins, Dyslipidemias, Atherosclerosis, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.